We build lifecycle programs that separate prescriber outreach from patient communication, respect consent rules that generic marketing CRMs ignore, and actually move refill and persistence numbers. No HubSpot workaround pretending to be Veeva.
The Problem
One CRM, two audiences, zero separation
Prescribers and patients get merged into the same contact database because it's faster to set up. HCP outreach then triggers patient-facing automations, or worse, patient data ends up in a system your medical affairs team never approved for that use. This isn't a data hygiene issue. It's a compliance exposure that shows up in an audit, not a dashboard.
Adherence programs built like ecommerce drip campaigns
Refill reminders and copay assistance enrollment get treated like abandoned-cart emails. They're not. Patients drop off a therapy for clinical, financial, and emotional reasons that a generic 3-email sequence doesn't address. Programs built without input from patient services or reimbursement teams see persistence curves flatten within two quarters.
Consent gets bolted on after the system is built
Healthcare communication consent isn't a checkbox at signup. It varies by channel, by state, and by whether the contact is a patient, caregiver, or HCP. Teams that build the CRM first and figure out opt-in later end up retrofitting consent logic into workflows that were never designed to hold it, which is how unauthorized outreach happens.
Veeva sits unused next to a marketing CRM nobody synced
Commercial teams pay for Veeva CRM because compliance requires it for HCP interactions, then run patient lifecycle marketing out of a separate tool with no integration. Field teams see stale prescriber data. Marketing has no visibility into call activity. Two systems of record means neither one is actually the record.
How We Help
We start by mapping every audience your organization actually communicates with: prescribers, patients, caregivers, and in some cases site coordinators or specialty pharmacy liaisons. Each of these needs its own consent model, its own data governance, and often its own system. We don't assume Veeva versus a marketing CRM is an either-or decision. For most biotech and pharma companies at your stage, it's both, with a defined boundary between them.
The assessment phase looks at what's actually happening today: where HCP and patient data live, what consent was captured and how, which state and channel-specific rules apply to your therapeutic area, and where your adherence or persistence numbers are dropping off. We pull this from your CRM exports, your patient services vendor if you have one, and interviews with whoever owns copay assistance and hub services operationally, not just the marketing team's view of the funnel.
From there we build the lifecycle architecture. On the HCP side, this usually means cleaning up how Veeva CRM data flows into any marketing automation you run for medical education or rep-triggered follow-up, so field teams and marketing aren't working from different pictures of the same prescriber. On the patient side, we design the actual programs: refill reminder cadences timed to therapy-specific dosing schedules, copay assistance enrollment flows that reduce the steps between diagnosis and first fill, and persistence check-ins that route to a live person, not another email, when a patient shows signs of discontinuing.
HIPAA-compliant infrastructure isn't a checkbox we add at the end. We build the communication layer, email, SMS, portal, or IVR depending on what your patient population actually uses, on infrastructure that supports business associate agreements and audit logging from day one. If you already have a hub services vendor handling PHI, we integrate around it rather than duplicating it.
Segmentation is where most generic marketing playbooks break down in pharma. A prescriber, a patient, and a caregiver need entirely different messages, different consent bases, and often different regulatory review paths for the content itself. We build segmentation logic that keeps these separate at the data layer, not just at the template layer, so a caregiver never receives content written for a prescriber and a patient's data never crosses into a channel they didn't consent to.
Measurement is built around the metrics that matter to a commercial or medical affairs leader, not generic marketing CRM dashboards. That means persistence rate at 90 and 180 days, copay enrollment completion rate, time from enrollment to first fill, and HCP engagement metrics tied to actual prescribing behavior where your data use agreements allow it. We report on these monthly, not quarterly, because adherence problems compound fast if they go unaddressed.
What makes this different from a generic CRM implementation partner: we've built these programs knowing that a patient persistence program and an HCP nurture sequence are not the same discipline wearing different templates. We bring in medical, legal, and regulatory review checkpoints as part of the build, not as a gate we hit after the fact and have to redo work around.
What we deliver
- HCP vs. patient vs. caregiver data architecture and consent mapping
- Veeva CRM to marketing automation integration or boundary definition
- HIPAA-compliant patient communication infrastructure (email, SMS, portal)
- Refill reminder and persistence program design tied to therapy dosing schedules
- Copay assistance and hub services enrollment flow optimization
- Channel and audience-specific consent/opt-in logic built into the CRM layer
- Monthly adherence and engagement reporting dashboard
A patient CRM and an HCP CRM solving the same problem are actually solving two different problems wearing the same acronym.
Our Methodology
We run this as a 90-day sprint broken into three phases. Days 1-30 are assessment and architecture: auditing existing CRM setups, mapping consent gaps, and defining where Veeva CRM and patient-facing systems need to connect versus stay separate. This phase ends with a documented data and consent architecture that your legal and compliance teams sign off on before we build anything.
Days 31-60 are build and integration. We stand up or reconfigure the patient communication infrastructure, wire up segmentation logic by audience type, and build the first adherence program, typically starting with whichever therapy or product line has the clearest persistence drop-off data. HCP-side integration work with Veeva happens in parallel if that's part of scope, coordinated with your field team leadership so nothing disrupts active rep activity.
Days 61-90 are launch and calibration. We run the first live cohort through the new lifecycle program, measure against baseline persistence and enrollment numbers, and adjust messaging cadence and channel mix based on what the data shows. By day 90 you have a working system, a governance document your compliance team trusts, and a reporting cadence that continues without needing us in the room every month.
How We Work
The first 30 days are diagnostic and we're in your systems directly, not asking your team to fill out a discovery questionnaire. We need to see the actual CRM configuration, the actual consent language patients agreed to, and the actual dropout points in your adherence data. This phase is intensive on our side and light on yours beyond access and a handful of working sessions.
Days 30-60 shift to build mode. You'll have a working session with us weekly, plus async check-ins as we hit decisions that need your medical affairs or legal sign-off, particularly around consent logic and any patient-facing message content. We don't wait until the end to loop in compliance. That's how these programs get stuck in review for months after they're technically done.
Team structure is typically two to three of us: someone owning the CRM and data architecture, someone owning the lifecycle program content and cadence design, and a lead who's in every compliance and stakeholder conversation. For companies with an existing patient services or hub vendor, we work alongside them rather than replacing their function.
Past day 90, most clients keep us on a lighter monthly cadence to refine programs as new therapies launch or as persistence data reveals new drop-off points. Some transition to fully in-house once the architecture and first programs are stable. If your biotech or pharma company needs lifecycle and CRM support, we should talk.
- Improved patient persistence and refill continuation rates
- Reduced time from enrollment to first fill in copay assistance programs
- Clean separation between HCP and patient data with documented consent logic
- Working integration between Veeva CRM and marketing automation instead of parallel disconnected systems
- Compliance-reviewed communication infrastructure that reduces audit risk
- A repeatable lifecycle program framework for future product launches
If your biotech & pharma company needs lifecycle & crm leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
Do we need both Veeva CRM and a separate marketing CRM, or can we consolidate into one system?
For most companies at your stage, you need both, because Veeva CRM handles HCP interaction compliance requirements that generic marketing tools don't support, while patient lifecycle programs need channel flexibility Veeva isn't built for. Consolidating into one system usually means compromising on one side or the other. We define a clear boundary and integration points between the two instead of forcing a merge.
How do you handle consent differently for patients versus prescribers?
Prescriber consent for HCP communication is typically governed by your existing Veeva-compliant processes and any state-level marketing-to-physician rules. Patient consent depends on the channel, the state, and whether PHI is involved, which means opt-in language and storage requirements differ by program. We map these separately at the start so the CRM enforces the right consent basis for each audience rather than applying one blanket policy.
Can you work with our existing hub services or patient support vendor?
Yes. Most of our clients already have a hub services or specialty pharmacy vendor handling parts of copay assistance or enrollment. We build our lifecycle programs to integrate with that vendor's data feeds rather than duplicating their function, so you're not paying twice for the same enrollment step.
What does a HIPAA-compliant patient communication setup actually require?
At minimum, it requires business associate agreements with any vendor touching PHI, audit logging on who accessed or sent what, and encryption in transit and at rest for patient data. It also requires the communication content itself to be built so PHI never appears in an unsecured channel like standard email without a secure portal layer. We assess your current setup against these requirements before recommending any new tooling.
How fast can we see movement in persistence or adherence numbers?
You'll see the first live cohort data by day 90, but meaningful persistence trends usually take two to three months beyond that to read clearly, since persistence is measured at 90 and 180-day marks. We report early directional signals, like enrollment completion rate, within the first 60 days so you're not waiting in the dark.
